Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics was planning to go public, but the IPO was withdrawn on Jun 9, 2025.
Stock Price: Pending
IPO price not available yet

Company Description

Odyssey is a clinical-stage biopharmaceutical company led by a team and board of drug hunters seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases.

To accomplish this, we are developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system.

Our most advanced programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, for which we intend to commence a Phase 2a monotherapy trial for ulcerative colitis in the first quarter of 2025 and a Phase 2a combination trial with vedolizumab in the first half of 2026.

Odyssey Therapeutics, Inc.
CountryUnited States
Founded2021
IndustryBiotechnology
SectorHealthcare
Employees151
CEOGary D. Glick, Ph.D.

Contact Details

Address:
51 Sleeper Street
Boston, MA 02210
United States
Phone(617) 865-9628
Websiteodysseytx.com

Stock Details

Ticker SymbolODTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001882782
Employer ID86-3384382
SIC Code2836

Key Executives

NamePosition
Gary D. Glick, Ph.D.President, Chief Executive Officer and Director
Julie ClaussChief Operating Officer
Jason HaasChief Financial Officer
William Roush, Ph.D.Executive Vice President, Head of Small Molecule Research
Kira M. SchwartzExecutive Vice President, General Counsel and Secretary
Stephen Soisson, Ph.D.Executive Vice President, Protein Therapeutics and Structural Biology
Collin ToddSenior Vice President, Strategy and Business Development
Jeffrey M. Leiden, M.D., Ph.D.Chair and Director
Charles Baum, M.D., Ph.D.Director
Jill CarrollDirector

Latest SEC Filings

DateTypeTitle
Jun 9, 2025RWFiling
Jan 17, 2025S-1General form for registration of securities under the Securities Act of 1933
Dec 5, 2024DRS/A[Amend] [Cover] Draft Registration Statement
Nov 18, 2024DRS/A[Amend] [Cover] Draft Registration Statement
Oct 7, 2024DRS[Cover] Draft Registration Statement
Aug 14, 2024D/AFiling
Dec 15, 2023DNotice of Exempt Offering of Securities
Oct 27, 2022DNotice of Exempt Offering of Securities
Oct 14, 2021DNotice of Exempt Offering of Securities